The FDA approved the first nonsteroidal drug to treat all genetic variants of Duchenne muscular dystrophy, clearing drugmaker Italfarmaco’s oral treatment for patients age 6 and older.
The drug, givinostat, will be sold as Duvyzat, the FDA said in a press release announcing the approval. It’s different than genetic medicines approved for Duchenne, such as exon-skipping drugs or gene therapy, which require patients to have certain mutations.
Duvyzat is a histone deacetylase inhibitor, taken twice a day orally. “It is not trying to restore the dystrophin, but it’s trying to counteract the downstream effect of the lack of dystrophin,” Paolo Bettica, Italfarmaco’s VP of R&D, told Endpoints News ahead of the decision. The approval follows a three-month delay by the FDA in December.
In a Phase 3 clinical trial of 179 boys with Duchenne who were walking and at least 6 years old, those who received Duvyzat performed better on a timed four-stair climb test than those who received placebo, according to a study published Tuesday in Lancet Neurology. The most common adverse events in the treatment group were diarrhea and vomiting.
Duchenne treatments have evolved substantially in the last decade, with accelerated approvals of four exon-skipping drugs for patients with certain mutations. The FDA last year granted a landmark accelerated approval to Sarepta’s gene therapy Elevidys for boys who are 4 and 5 years of age. And the agency is expected to decide by June whether to expand Elevidys’ label to a wider age range and whether to convert it to a full approval.
Thursday’s approval of Italfarmaco’s drug also could open the door to combination approaches for treating Duchenne.
“Given the mechanism of action and given what is happening, this is something that potentially in the future we might be considering and studying,” Bettica said.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Unraveling CRISPR Precision: BreakTag Illuminates Pathways to Improved Gene Editing
Introduction:The quest for precision in CRISPR-Cas9 gene editing takes a significant leap forward with the development of BreakTag, a method devised to enhance our understanding of DNA double-strand breaks (DSBs) induced by Cas9. This breakthrough, detailed in a...
Promising Early Results for Gene Therapy DB-OTO in Treating Genetic Deafness
Regeneron Pharmaceuticals, Inc. recently shared encouraging early results from the ongoing Phase I/II CHORD trial of DB-OTO, a gene therapy aimed at treating genetic deafness caused by variants of the otoferlin gene. The data was presented at the American Society of...
Groundbreaking CoCas9 Enzyme Unveiled: A Compact and Efficient CRISPR Tool for Genetic Therapy
Introduction: A revolutionary stride has been made in the field of genetic engineering, as researchers from the University of Trento introduce a novel CRISPR enzyme, CoCas9, which promises to enhance the delivery and efficacy of in vivo gene therapy using...
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
Avidity initiating global Phase 3 HARBOR™ study for delpacibart etedesiran this quarter Delpacibart etedesiran data from MARINA-OLE™ showed reversal of disease progression in multiple functional measures in DM1 compared to END-DM1 natural history data SAN DIEGO, May...
Related Services